This patent is important for the TTS project and comprises the possibility to use TTS as combination therapy.
This patent is the first in a series of applications related to combination of TTS and other established pharmaceuticals for cancer treatment.
The patent is valid until 2018.
The TTS patent portfolio in the U.S. consist of six separate patent families. With this new patent approval, three families are granted in the U.S. and the remaining are under review.
In Europe, Active Biotech has seven patent families whereof three are granted.The applications related to combination therapies are under review.
The U.S. Food and Drug Administration (FDA) granted fast track status to Active Biotech's candidate drug TTS CD3 for the treatment of non-small cell lung cancer on December 1.
Lund, December 2, 2004
Active Biotech AB (publ)
Sven Andréasson
President & CEO
Active Biotech AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases, as well as a novel concept for use in cancer immunotherapy.
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50